期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 26, 期 3, 页码 590-602出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2017.12.020
关键词
Casein kinase 1 delta and epsilon; Kinase; Inhibitor; Structure-activity relationship; Breast cancer
资金
- NIH NCI [R01CA175094]
- NIH NCI NRSA [F32CA200105]
Casein kinase 1 delta/epsilon have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1 delta/epsilon inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据